Intra-Cellular Therapies Inc (NASDAQ:ITCI) EVP Michael Halstead sold 3,108 shares of the company’s stock in a transaction that occurred on Monday, January 7th. The stock was sold at an average price of $12.42, for a total transaction of $38,601.36. Following the completion of the transaction, the executive vice president now owns 24,757 shares of the company’s stock, valued at $307,481.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Halstead also recently made the following trade(s):

  • On Friday, January 4th, Michael Halstead sold 21,458 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $11.46, for a total transaction of $245,908.68.

ITCI stock opened at $13.14 on Friday. Intra-Cellular Therapies Inc has a one year low of $10.21 and a one year high of $25.82. The firm has a market capitalization of $718.01 million, a PE ratio of -6.20 and a beta of 1.30.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.09. As a group, research analysts expect that Intra-Cellular Therapies Inc will post -2.95 EPS for the current fiscal year.

A number of research firms have weighed in on ITCI. Leerink Swann reiterated an “outperform” rating on shares of Intra-Cellular Therapies in a research report on Friday, October 19th. Zacks Investment Research lowered shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Thursday. Cantor Fitzgerald reiterated a “buy” rating and issued a $32.00 price target on shares of Intra-Cellular Therapies in a research report on Thursday, October 4th. ValuEngine lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Thursday, November 15th. Finally, BidaskClub raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a report on Friday, September 28th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. Intra-Cellular Therapies presently has an average rating of “Buy” and an average price target of $27.75.

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc lifted its holdings in shares of Intra-Cellular Therapies by 1.8% in the third quarter. Vanguard Group Inc now owns 3,943,792 shares of the biopharmaceutical company’s stock worth $85,580,000 after buying an additional 69,950 shares in the last quarter. Vanguard Group Inc. raised its stake in Intra-Cellular Therapies by 1.8% during the third quarter. Vanguard Group Inc. now owns 3,943,792 shares of the biopharmaceutical company’s stock valued at $85,580,000 after purchasing an additional 69,950 shares in the last quarter. MetLife Investment Advisors LLC raised its stake in Intra-Cellular Therapies by 55.8% during the third quarter. MetLife Investment Advisors LLC now owns 30,540 shares of the biopharmaceutical company’s stock valued at $663,000 after purchasing an additional 10,934 shares in the last quarter. Point72 Asset Management L.P. raised its stake in Intra-Cellular Therapies by 234.2% during the third quarter. Point72 Asset Management L.P. now owns 634,466 shares of the biopharmaceutical company’s stock valued at $13,768,000 after purchasing an additional 444,609 shares in the last quarter. Finally, Tekla Capital Management LLC purchased a new stake in Intra-Cellular Therapies during the third quarter valued at $756,000. 69.53% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Intra-Cellular Therapies Inc (ITCI) EVP Sells $38,601.36 in Stock” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/intra-cellular-therapies-inc-itci-evp-sells-38601-36-in-stock/2739442.html.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

Read More: How do taxes affect a CDs total return?

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.